title: The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
abstract: From 1981 to 1984, a randomized study was done by the EORTC Radiotherapy Group comparing a fractionation schedule with three fractions per day (multiple fractions per day, MFD), with or without misonidazole, to conventional fractionation. The aim of the study was to obtain improved local and regional control and survival by shortening of the treatment time in the first 2 weeks of irradiation. Three fractions of 1.6 Gy/day (4-h interval) were given during 10 irradiation days to a total of 48 Gy. After 3-4-weeks interval, a boost was given to 67.2 or 72 Gy also in three fractions per day. This schedule was compared to an identical arm with misonidazole 1 g/m2/day and a third arm with conventional fractionation (70 Gy in 35 fractions, 7 weeks or 75 Gy in 44 fractions, 9 weeks). A total number of 523 patients was included in the study. Acute mucositis was much heavier in patients treated with three fractions per day (Van den Bogaert et al. Int. J. Radiat. Oncol. Biol. Phys. 8: 1649-1655, 1982). Early results, communicated in 1986 (Van den Bogaert et al. Int. J. Radiat. Oncol. Biol. Phys. 12: 587-591, 1986) showed no differences in treatment outcome between the three treatment arms. Long-term results and data on late effects are now available. Survival at 5 years was 18% (SE 1.9%) and locoregional control was 27% (SE 2.9%). No statistically significant differences could be observed between the three treatment arms.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Radiotherapy Department, University Hospital, Gasthuisberg, Leuven, Belgium.
authors.forename: W
authors.initials: W
authors.lastname: Van den Bogaert
authors.forename: E
authors.initials: E
authors.lastname: van der Schueren
authors.forename: J C
authors.initials: JC
authors.lastname: Horiot
authors.forename: M
authors.initials: M
authors.lastname: De Vilhena
authors.forename: S
authors.initials: S
authors.lastname: Schraub
authors.forename: V
authors.initials: V
authors.lastname: Svoboda
authors.forename: G
authors.initials: G
authors.lastname: Arcangeli
authors.forename: M
authors.initials: M
authors.lastname: de Pauw
authors.forename: M
authors.initials: M
authors.lastname: Van Glabbeke
mesh_terms: D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008920:Misonidazole / Q000008:administration & dosage* / Q000009:adverse effects; D011832:Radiation Injuries / Q000473:pathology; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D015996:Survival Rate
chemical_list: D011838:Radiation-Sensitizing Agents; D008920:Misonidazole